Galectin Therapeutics (NASDAQ:GALT) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note published on Saturday morning. The brokerage issued a hold rating on the stock. Separately, HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a research report on Tuesday, August 15th. […]

Related Keywords

,Geode Capital Management ,Investors Services ,Galectin Therapeutics Inc ,Financial Services Group Inc ,Northern Trust Corp ,Galectin Therapeutics ,Free Report ,Get Free Report ,Trust Corp ,Capital Management ,Services Group ,State Street Corp ,Street Corp ,Therapeutics Inc ,Galectin Therapeutics Daily ,Nasdaq Galt ,Galt ,Medical ,Initiated Coverage ,Stocknews Com ,